Alps Advisors Inc. lessened its holdings in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 4.3% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 67,599 shares of the specialty pharmaceutical company’s stock after selling 3,068 shares during the period. Alps Advisors Inc. owned about 0.20% of AMAG Pharmaceuticals worth $781,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Russell Investments Group Ltd. lifted its position in AMAG Pharmaceuticals by 12.0% during the third quarter. Russell Investments Group Ltd. now owns 101,700 shares of the specialty pharmaceutical company’s stock valued at $1,175,000 after acquiring an additional 10,900 shares during the last quarter. California Public Employees Retirement System increased its stake in AMAG Pharmaceuticals by 11.8% during the 3rd quarter. California Public Employees Retirement System now owns 80,327 shares of the specialty pharmaceutical company’s stock valued at $928,000 after purchasing an additional 8,474 shares in the last quarter. State of Tennessee Treasury Department increased its stake in AMAG Pharmaceuticals by 10.4% during the 3rd quarter. State of Tennessee Treasury Department now owns 25,899 shares of the specialty pharmaceutical company’s stock valued at $299,000 after purchasing an additional 2,435 shares in the last quarter. Rhumbline Advisers increased its stake in AMAG Pharmaceuticals by 5.0% during the 3rd quarter. Rhumbline Advisers now owns 114,850 shares of the specialty pharmaceutical company’s stock valued at $1,327,000 after purchasing an additional 5,457 shares in the last quarter. Finally, Virginia Retirement Systems ET AL increased its stake in AMAG Pharmaceuticals by 5.5% during the 3rd quarter. Virginia Retirement Systems ET AL now owns 84,800 shares of the specialty pharmaceutical company’s stock valued at $979,000 after purchasing an additional 4,400 shares in the last quarter.
AMAG traded up $0.02 during midday trading on Wednesday, hitting $10.70. 664,745 shares of the company traded hands, compared to its average volume of 892,463. The company has a current ratio of 1.67, a quick ratio of 1.53 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $361.14 million, a price-to-earnings ratio of -2.76 and a beta of 0.35. AMAG Pharmaceuticals, Inc. has a 52-week low of $6.81 and a 52-week high of $18.39. The business has a 50 day simple moving average of $10.56 and a two-hundred day simple moving average of $10.35.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Friday, November 1st. The specialty pharmaceutical company reported ($0.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by ($0.19). The company had revenue of $84.13 million for the quarter, compared to analysts’ expectations of $88.25 million. AMAG Pharmaceuticals had a negative net margin of 88.54% and a negative return on equity of 34.59%. The business’s revenue for the quarter was down 31.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.89 earnings per share. Equities research analysts anticipate that AMAG Pharmaceuticals, Inc. will post -2.48 earnings per share for the current year.
A number of research analysts have issued reports on the stock. Barclays restated a “buy” rating and set a $14.00 price target (down previously from $16.00) on shares of AMAG Pharmaceuticals in a research note on Sunday, November 3rd. Needham & Company LLC restated a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Friday, October 25th. BidaskClub upgraded shares of AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 23rd. Piper Jaffray Companies lowered shares of AMAG Pharmaceuticals from a “neutral” rating to an “underweight” rating and cut their price objective for the stock from $9.00 to $6.00 in a research note on Wednesday, October 30th. Finally, HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of AMAG Pharmaceuticals in a research note on Thursday, August 8th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $13.28.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Featured Story: Profit Margin
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.